GTx, Inc. (NASDAQ: GTXI)

Sector: Medical

Current Price : $5.89

52 Week Low
$2.7152 Week High
$5.89

Press Releases
GTx Provides Corporate Update and Reports First Quarter 2013 Financial Results
GTx Initiating Phase 2, Open-Label Study of Enobosarm to Treat ER Positive Metastatic Breast Cancer
GTx, Inc. To Host First Quarter 2013 Financial Results Conference Call and Webcast
GTx's Phase III Clinical Studies of Enobosarm (GTx-024) to Continue as Planned Following Planned Safety Review
Enobosarm Phase 2 Trial for Muscle Wasting and Physical Function in Patients with Cancer Published in The Lancet Oncology
GTx Announces Webcast of Corporate Presentation at Cowen and Company 33rd Annual Health Care Conference
GTx Provides Corporate Update and Reports 2012 Financial Results
GTx Announces Webcast of Corporate Presentation at 2013 Citi Global Healthcare Conference
GTx To Present Preclinical Data on a New Therapeutic Target in Prostate Cancer
Novel Findings from Clinical Studies Examining the Effects of Capesaris? (GTx-758) for the Treatment of Advanced Prostate Cancer to be Presented at 2013 American Society of Clinical Oncology Genitourinary Cancer Symposium
GTx Announces Webcast for Capesaris?(GTx-758) Analyst Day
GTx, Inc. to Host Fourth Quarter and Full Year 2012 Financial Results Conference Call and Webcast
GTx Announces Webcast of Corporate Presentation at Bio CEO & Investor Conference
GTx Announces FDA's Grant of Fast Track Designation to Enobosarm For the Prevention and Treatment of Muscle Wasting in patients with Non-Small Cell Lung Cancer
GTx Attains Enrollment Goal for its Enobosarm POWER 1 and POWER 2 Phase III Clinical Studies
GTx Provides Corporate Update and Reports Third Quarter 2012 Financial Results
GTx Announces Webcast of Corporate Presentation at Jefferies 2012 Global Healthcare Conference
GTx Announces Webcast of Corporate Presentation at Lazard Capital Markets 9th Annual Healthcare Conference
GTx's Phase III Clinical Development of Enobosarm (GTx-024) for muscle wasting in lung cancer patients on Course Following Planned Safety Review
GTx, Inc. To Host Third Quarter 2012 Financial Results Conference Call and Webcast
GTx to Present Scientific Poster Presentations on Enobosarm to Prevent and Treat Muscle Wasting in Cancer Patients
GTx Announces Sale of Fareston?
GTx Announces Presentation on the Ability of Capesaris? to Reduce Free Testosterone and Suppress PSA in Men With Castration Resistant Prostate Cancer
GTx Announces Symposium and Presentation of Data on Muscle Wasting In Non-Small Cell Lung Cancer Patients
GTx Announces Webcast of Corporate Presentation at NewsMakers in the Biotech Industry Conference
GTx Provides Corporate Update and Reports Second Quarter 2012 Financial Results
GTx Announces Webcast of Corporate Presentation at Wedbush 2012 Life Sciences: Management Access Conference
GTx, Inc. To Host Second Quarter 2012 Financial Results Conference Call and Webcast
GTx Announces Presentations on the Effect of Enobosarm on Improving Physical Function In Cancer Patients
GTx Announces Presentation on Enobosarm's Improvement in Physical Function in Cancer Patients with Both Low and Normal Testosterone Levels
GTx Announces Panel Presentation On Muscle Wasting In Non-Small Cell Lung Cancer Patients
GTx Announces Poster Presentation on the Prevalence and Impact of Hypogonadism in Cancer Patients with Muscle Wasting from its Phase IIb Enobosarm Clinical Trial at the Endocrine Society's 2012 Annual Meeting
GTx Announces Webcast of Corporate Presentation at Jefferies 2012 Global Healthcare Conference
GTx Provides Corporate Update and Reports First Quarter 2012 Financial Results
GTx Announces Removal of Full Clinical Hold By FDA for Capesaris? In Advanced Prostate Cancer
GTx, Inc. To Host First Quarter 2012 Financial Results Conference Call and Webcast
GTx Submits Clinical Hold Complete Response Letter To FDA For Its Planned Phase II Clinical Study Of Capesaris? For Secondary Hormonal Therapy of Advanced Prostate Cancer
GTx Announces Webcast of Corporate Presentation at the Cowen and Co. Annual Health Care Conference
GTx Announces Webcast of Corporate Presentation at the Citi 2012 Global Health Care Conference
GTx Provides Corporate Update and Reports 2011 Financial Results
GTx Announces Clinical Hold on Clinical Trials Evaluating Capesaris? for First and Second Line Treatments of Advanced Prostate Cancer
GTx, Inc. To Host Fourth Quarter and Full Year 2011 Financial Results Conference Call and Webcast
GTx Announces Webcast of Corporate Presentation at the Lazard Capital Markets Annual Healthcare Conference
GTx, Inc. Provides Corporate Update and Reports Third Quarter 2011 Financial Results
GTx Announces Panel Discussion at Citi's 6th Annual Biotech Day
GTx Announces Webcast of Corporate Presentation at the 2011 Wedbush Life Sciences Conference
GTx, Inc. Provides Corporate Update and Reports Second Quarter 2011 Financial Results
GTx, Inc. To Host Second Quarter 2011 Financial Results Conference Call and Webcast
GTx Announces Upcoming Presentations of Effects of Ostarine(TM) in Non-Small Cell Lung Cancer Patients at World Conference on Lung Cancer
GTx Initiates Phase IIb Clinical Trial Evaluating?Oral?Capesaris(TM)?Tablets Versus Lupron?Depot(R)?for First Line Treatment of Advanced Prostate Cancer
GTx Set to Join Russell 3000 Index
GTx Announces Agreement with FDA on Phase III Clinical Development Plan Evaluating Ostarine(TM) (GTx-024) for the Prevention and Treatment of Muscle Wasting in Patients with Non-Small Cell Lung Cancer
GTx Announces Webcast of Corporate Presentation at the Jefferies 2011 Global Healthcare Conference
GTx Presents Preclinical Study Results Demonstrating That Capesaris(TM) (GTx-758) Chronic Treatment Does Not Cause Gynecomastia in Male Primates
GTx, Inc. To Host First Quarter 2011 Financial Results Conference Call and Webcast
GTx and Ipsen Terminate Their Toremifene Collaboration
GTx Announces Webcast of Corporate Presentation at the Cowen and Company Annual Health Care Conference
GTx Provides Corporate Update and Reports 2010 Financial Results
GTx Announces Webcast of Corporate Presentation at the Citi 2011 Global Health Care Conference
GTx Announces Presentation at the ASCO Genitourinary Cancers Symposium of Additional Study Results from the Phase III Clinical Trial Evaluating Toremifene 80 mg for the Reduction of Fractures in Men with Prostate Cancer on ADT
GTx, Inc. To Host Fourth Quarter and Year End 2010 Financial Results Conference Call and Webcast
GTx Announces Webcast of Corporate Presentation at the JP Morgan Healthcare Conference

Two Week FREE Trial

iStock Rating

GTx, Inc. (NASDAQ: GTXI)

Sector: Medical

Company

Community

Analysis

Charts

Analyst

Ratios